Zhang Hang, Zhang Ruoyu, Yu Min, Yuan Zhongxiang, Qian Dewei, Chen Wen, Huang Fuhua, Chen Xin, Wang Xiaodi
Department of Thoracic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Thoracic and Cardiovascular Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
BMC Cardiovasc Disord. 2025 Jan 27;25(1):52. doi: 10.1186/s12872-025-04506-0.
The aim of this study was to investigate whether the hybrid technique yields superior outcomes in comparison with the total arch replacement combined with frozen elephant trunk (TAR + FET) for acute aortic dissection (AAD) involving the aortic arch.
This retrospective cohort study using propensity-score matching included patients with AAD involving the aortic arch admitted to Nanjing First Hospital and Shanghai General Hospital from January 2015 to June 2020. The in-hospital and mid-term outcomes were compared between patients who received hybrid treatment (n = 136) and those who received TAR + FET (n = 415). Study end points included in-hospital mortality and morbidity, and mid-term rates of death from all causes, stroke, and aortic re-intervention.
A total of 121 pairs were formed after matching. In-hospital mortality did not differ between hybrid versus TAR + FET groups (5.8% vs. 7.9%, P = .860). Up to 6 years, patients treated with TAR + FET were associated with reduced rate of aortic re-intervention (HR 0.21, 95% CI 0.05-0.97; P = .023). There was no difference in death from all causes and stroke.
Hybrid technique and TAR + FET showed comparable mid-term survival. Hybrid technique showed higher rate of aortic re-intervention and should therefore be applied with great caution in patients with AAD involving the aortic arch.
本研究旨在探讨对于累及主动脉弓的急性主动脉夹层(AAD),杂交技术与全弓置换联合象鼻支架植入术(TAR + FET)相比是否能产生更好的疗效。
本项回顾性队列研究采用倾向评分匹配法,纳入了2015年1月至2020年6月期间在南京第一医院和上海交通大学医学院附属瑞金医院住院治疗的累及主动脉弓的AAD患者。比较接受杂交治疗的患者(n = 136)和接受TAR + FET治疗的患者(n = 415)的院内及中期结局。研究终点包括院内死亡率和发病率,以及全因死亡率、卒中率和主动脉再次干预率的中期数据。
匹配后共形成121对。杂交组与TAR + FET组的院内死亡率无差异(5.8%对7.9%,P = 0.860)。长达6年的随访结果显示,接受TAR + FET治疗的患者主动脉再次干预率较低(HR 0.21,95%CI 0.05 - 0.97;P = 0.023)。全因死亡率和卒中率无差异。
杂交技术和TAR + FET的中期生存率相当。杂交技术的主动脉再次干预率较高,因此在累及主动脉弓的AAD患者中应用时应格外谨慎。